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Abstract
Background: Mathematical models can be developed to predict growth in short children treated with growth
hormone (GH). These models can serve to optimize and individualize treatment in terms of height outcomes and
costs. The aims of this study were to compile existing prediction models for short children born SGA (SGA), to
develop new models and to validate the algorithms.
Methods: Existing models to predict height velocity (HV) for the first two and the fourth prepubertal years and
during total pubertal growth (TPG) on GH were applied to SGA children from the KIGS (Pfizer International Growth
Database) - 1
st year: N = 2340; 2
nd year: N = 1358; 4
th year: N = 182; TPG: N = 59. A new prediction model was
developed for the 3
rd prepubertal year based upon 317 children by means of the all-possible regression approach,
using Mallow’s C(p) criterion.
Results: The comparison between the observed and predicted height velocity showed no significant difference
when the existing prediction models were applied to new cohorts. A model for predicting HV during the 3
rd year
explained 33% of the variability with an error SD of 1.0 cm/year. The predictors were (in order of importance): HV
previous year; chronological age; weight SDS; mid-parent height SDS and GH dose.
Conclusions: Models to predict growth to GH from prepubertal years to adult height are available for short
children born SGA. The models utilize easily accessible predictors and are accurate. The overall explained variability
in SGA is relatively low, due to the heterogeneity of the disorder. The models can be used to provide patients with
a realistic expectation of treatment, and may help to identify compliance problems or other underlying causes of
treatment failure.
Background
Small for gestational age (SGA) is a working diagnostic
term used to describe foetuses or newborn infants who
have a lower weight and/or length than what is normal
for their gestational age, in the absence of any other
specific diagnosis or reason for their small stature [1].
Although in the majority of children born SGA catch-
up growth occurs by 2 years of age, in about 10% catch-
up growth does not occur. Without treatment, these
children remain short and constitute some 20-25% of
adults whose final height is below -2 SD scores [2].
Although, these individuals are not growth hormone
(GH) deficient, recent long-term studies have shown
that treatment with recombinant human GH is able to
improve height. Today GH has become an approved
treatment in promoting catch-up growth [3] in short
children born SGA. Experience with SGA children trea-
ted with GH to adult height is still very limited and stu-
dies have shown that a considerable fraction of the
children treated does not achieve an adult height within
the normal range. These observations demand an
improved and individualized therapy with GH in short
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for the optimization of GH in SGA have been published
based on patients documented within KIGS [4,5]. The
aim of this study is to test the existing prediction mod-
els and to develop additional growth prediction model
from the KIGS database, to allow an optimisation and
individualization of GH treatment from pre-pubertal
onset to the end of the growth phase in SGA.
Methods
Patients
Patients included in this analysis were receiving recombi-
nant human GH (Genotropin
®; Pfizer Inc.) during follow-
up and were documented in the pharmacoepidemiological
survey - KIGS (Pfizer International Growth Database) by
July 18, 2010. The KIGS survey is conducted in accor-
dance with the Declaration of Helsinki [6]. Diagnosis was
made according to the KIGS aetiology classification list
[7]. Additional inclusion criteria for the patients were a
birth weight and/or birth length for gestational age below
-2.0 SD scores. Pre-pubertal stage was defined as a mean
testes volume ≤ 3 ml in boys or Tanner breast stage B1 in
girls. All patients received six or seven injections of GH
per week. In order to avoid the effects of initial catch-up
growth on total pubertal growth (TPG) only patients who
were treated with GH for a total of at least 5 years and
who were treated at least two years before puberty onset
were included in the analysis of TPG.
The height standards used for normal children were
those of Tanner et al [8] or - as indicated - those of
Prader et al. [9] and the weight standards were those of
Freeman et al. [10]. Birth weight for gestational age was
transformed to an SD score based on the standards of
Niklasson et al [11]. The MPH SD score was calculated
as: (father’s height SD score + mother’s height SD score)
÷ 1.61 [12]. Bone ages, calculated according to the
method of Greulich and Pyle [13], were taken as
reported by the treating physician.
The existing prediction models for the first two prepu-
bertal years for short children born SGA [4] were tested
on children documented within KIGS by July 18, 2010.
The characteristics of the patients used for the develop-
ment of prediction models for the first two prepubertal
years are listed in Table 1. The existing prediction mod-
els for total pubertal growth (TPG) developed for boys
and girls with idiopathic GHD [5] were tested for
applicability to SGA children.
Development of the prediction model
Growth responses (annualized height velocities) during
GH therapy were correlated, by multiple regression ana-
lysis, with potentially relevant variables as published
before [14]. It was attempted to develop prediction
models for the third and fourth pre-pubertal year on
GH. The variables tested were (i) status at birth: sex,
weight SD score, length SD score, ponderal index, mode
of delivery and APGAR score; (ii) genetic background:
height SD score of the mother, height SD score of the
father, and midparental height (MPH) SD score; (iii)
treatment modality: GH dose (per kg body weight and
per kg ideal body weight [weight for height]), frequency
of GH injections, and accumulated years of GH treat-
ment; (iv) patient variables at the beginning of the treat-
ment period: age, bone age, height SD score, weight SD
score, height SD score minus MPH SD score, the peak
serum GH concentration during stimulation testing and
the height velocity during the previous year of GH
treatment.
Statistical analysis
Variables are reported as mean and standard deviation.
SD scores were calculated as follows: SD score =
(patient value - mean value for age- and sex-matched
normal subjects) ÷ SD of the value for age- and sex-
matched normal subjects. For comparison of patient
groups, Student’s t-test was used if data had a Gaussian
distribution, and Wilcoxon’s rank-sum test was used
otherwise. Significance was considered at the 1% level
(P < 0.01), unless otherwise specified. SAS
® version 8
for Sun Solarix (SAS Institute, Cary, North Carolina)
was used for all statistical analyses. The prediction mod-
els were developed by means of a multiple linear regres-
sion analysis fitted by least squares and the REG
procedure in the SAS computer program (version 8.02,
Table 1 Characteristics of the SGA patients used for the
development of the SGA growth prediction models
1
st prepubertal
year
2
nd prepubertal
year
N Mean SD N Mean SD
At GH treatment start
Sex male % 67 62
Birth weight SDS 613 -2.7 1.0 385 -2.6 1.0
Birth length SDS 465 -2.7 1.3 295 -2.7 1.3
Maximum GH peak (ng/ml) 613 20.8 13.3 385 20.9 13.6
MPH SDS 607 -0.9* 1.2 379 -0.8* 1.2
Age (years) 613 6.6 2.5 385 6.3 2.2
Height SDS 613 -2.8* 0.9 385 -2.8* 0.9
Weight SDS 613 -3.4 1.6 385 -3.4 1.6
GH dose (mg/kg/day) 613 0.04 0.02 385 0.04 0.02
First-year growth response
HV(cm/year) 613 8.6 1.9 385 8.7 1.8
Change in (delta) height SDS 613 0.7* 0.4 385 0.7* 0.3
Second year growth response
HV(cm/year) 385 7.0 1.4
Change in (delta) height SDS 385 0.3* 0.2
The first and second pre-pubertal years on GH [4] are shown.
* = calculations based on Tanner’s references [8].
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factors was derived by the all-possible regression
approach, using Mallow’s C (p) criterion for ordering
predictive factors, as described previously [15,16]. Dif-
ferences between observed and predicted height veloci-
ties were expressed in terms of Studentized Residuals.
The residual is calculated as the observed height velo-
city minus the predicted height velocity for each
observation, and the Studentized Residual is the resi-
dual divided by its standard error, which is equivalent
to a SD score.
Results
Response to GH: 1
st prepubertal year
A total of 2340 short children (62% boys) born SGA
were treated a full first year with GH. The characteris-
tics at start of GH treatment and the responses to GH
are listed in Table 2. The characteristics of the patients
and the parameters relevant for the developed first-year
prediction model [4] are listed in Table 1. The patients
were started on GH at an age of 7.2 (+/- 3.2) years and
a height of -3.4 (+/- 1.0) SDS. The height velocity
was 8.5 (+/- 2.1) cm/year and the delta height was 0.75
(+/- 0.44) SDS. The predicted height velocity was 8.8
(+/- 1.1) cm/year, which resulted in an SR of -0.27 (+/-
1.3 (see Table 2).
Response to GH: 2
nd prepubertal year
A total of 1358 short stature children (65% boys) born
SGA were treated a full second year with GH. The char-
acteristics at start of GH treatment and the responses to
GH are listed in Table 2. The characteristics of the
patients and the parameters relevant for the developed
second-year prediction model [4] are listed in Table 1.
The patients were started on GH at an age of 6.7 (+/-
2.8) years and a height of -3.5 (+/- 1.0) SDS. The height
velocity during the second year was 7.2 (+/- 1.5)
cm/year and the delta height was 0.45 (+/- 0.28) SDS.
The predicted height velocity was 7.1 (+/- 0.7) cm/year,
which resulted in an SR of 0.04 (+/- 1.2).
Table 2 Characteristics of the SGA patients used for the present analysis
1
st pre-pubertal year 2
nd pre-pubertal year 3
rd pre-pubertal year 4
th pre-pubertal year
N Mean SD N Mean SD N Mean SD N Mean SD
At GH treatment start
Sex male % 2340 62 1358 65 317 72 182 62
Birth weight SDS 2339 -2.6 1.0 1357 -2.6 1.0 316 -2.6 1.0 181 -2.8 1.0
Birth length SDS 1927 -2.5 1.3 1132 -2.6 1.3 254 -2.8 1.4 155 -3.1 1.4
Maximum GH peak (ng/ml) 1324 19.5 13.6 804 20.2 14.6 221 19.2 14.4 116 21.2 15.4
MPH SDS 2157 -1.2 1.2 1253 -1.1 1.2 317 -0.9 1.3 167 -0.7 1.3
Age (years) 2340 7.2 3.1 1358 6.7 2.8 315 5.5 2.1 182 3.7 0.9
Height SDS 2340 -3.4 1.0 1358 -3.5 1.0 317 -3.7 1.1 182 -4.2 1.3
Weight SDS 2340 -3.1 1.5 1358 -3.2 1.5 317 -3.6 1.7 182 -4.2 1.9
HV(cm/year) 756 5.4 1.9 486 5.5 1.9 140 5.6 3.7 88 6.5 2.1
GH dose (mg/kg/week) 2340 0.30 0.10 1358 0.31 0.11 317 0.30 0.11 182 0.31 0.11
First-year growth response
HV (cm/year) 2340 8.5 2.1 1358 8.7 2.0 310 9.0 2.0 173 9.5 2.0
Change in (delta) height SDS 2340 0.75 0.44 1358 0.79 0.43 310 0.82 0.43 173 1.0 0.5
Second year growth response
HV(cm/year) 1358 7.2 1.5 317 7.4 1.4 174 7.9 1.5
Change in (delta) height SDS 1358 0.45 0.28 310 0.47 0.27 174 0.6 0.3
Third year growth response
HV(cm/year) 317 6.6 1.2 182 6.9 1.4
Change in (delta) height SDS 317 0.32 0.22 182 0.31 0.29
Fourth year growth response
HV(cm/year) 182 6.1 1.2
Change in (delta) height SDS 182 0.20 0.25
Observed vs. predicted 1
st yr 2
nd yr 3
rd yr 4
th yr
Predicted HV(cm/yr) 1895 8.84 1.13 1104 7.08 0.67 317 6.60 0.71 171 6.19 0.78
Observed HV (cm/yr) 1895 8.48 1.90 1104 7.13 1.45 317 6.60 1.24 171 6.10 1.17
Student. Residual (SDS) 1895 -0.27 1.29 1104 0.04 1.22 317 0.00 1.01 171 -0.10 1.19
1st, 2nd, 3rd and 4th prepubertal years and the comparison between observed and predicted height velocities within respective years are shown.
Calculated derivates of height data (SDS, MPH) are based on Prader’s references [9].
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rd prepubertal year
A total of 317 short stature children (72% boys) born
SGA were treated a full third year with GH. The charac-
teristics at start of GH treatment and the responses to
GH are listed in Table 2. The patients were started on
GH at an age of 5.5 (+/- 2.1) years and a height of -3.7
(+/- 1.1) SDS. The height velocity during the third year
was 6.6 (+/- 1.2) cm/year and the delta height was 0.32
(+/- 0.22) SDS. The group was used to develop a third-
year prediction model for SGA (see below).
Response to GH: 4th prepubertal year
A total of 182 short stature children (62% boys) born
SGA were treated a full fourth year with GH. The char-
acteristics at start of GH treatment and the responses to
GH are listed in Table 2. The patients were started on
GH at an age of 3.7 (+/- 0.9) years and a height of -4.2
(+/- 1.3) SDS. The height velocity during the fourth year
was 6.1 (+/- 1.2) cm/year and the delta height was 0.20
(+/- 0.25) SDS. The predicted height velocity based on
the fourth year prediction model of GHD patients [14]
was 6.2 (+/- 0.8) cm/year, which resulted in an SR of
-0.10 (+/- 1.2).
Response to GH: Total pubertal growth (TPG)
In 35 male patients whose puberty started at an age of
12.9 (+/- 1.1) years and a height of 140.1 (+/- 6.8) cm,
and who received a mean GH dose of 0.26 (+/-0.1) mg/
kg/week TPG was 23.0 (+/-6.2) cm. In 24 female
patients whose puberty started at an age of 11.8 (+/-
1.8) years and a height of 135.4 (+/- 7.2) cm, and who
received a mean GH dose of 0.25 (+/-0.1) mg/kg/week
TPG was 17.3 (+/-6.3) cm. Based on the prediction
models developed for TPG of males and females with
GHD [17] the predicted TPG for boys and girls were
26.3 (+/-5.1) and 18.0 (+/-5.7) cm. These predicted
numbers for height gain during puberty are not different
from those actually observed.
3
rd year prepubertal prediction model for short children
born SGA
The results of the development of the prediction model
for the 3
rd prepubertal year based on 317 children (see
Table 2) are listed in Table 3. Table 3 also gives the
rank order of importance of the variables as predictors,
the overall correlation coefficients of the prediction
models (R
2) and the error SD of the prediction in centi-
metres. The equation describing the predicted height
velocity (PHV) for the third year of GH therapy (from
Table 3) is as follows: PHV (cm/year) = 6.2 + [-0.18 ×
age at start (years)] + [0.19 × weight SD score at start]
+[ 1 . 2 1×G Hd o s e( m g / k g / w e e k ) ]+[ 0 . 1 2×M P HS D
s c o r e ]+[ 0 . 2 6×H V2
nd year (cm/year)] ± 1.0. The
equation explains 33% of the variability.
The difference between observed and predicted
height velocity during the first to fourth prepubertal
year and of observed and predicted total growth during
puberty expressed in terms Studentized are illustrated
in Figures 1 a-e.
Validation of 3
rd year prepubertal prediction model for
SGA children
A subgroup of 34 children was randomly assigned from
the total cohort identified for the validation of the derived
model. The characteristics of these patients were not dif-
ferent compared to model group. The correlation between
Table 3 Regression equation variables for prediction of the growth response to GH therapy during various treatment
periods in short children born SGA
Prepubertal years Total pubertal growth
1
st year 2
nd year 3
rd year 4
th year
(@) male
(@) female
(@)
Parameter Parameter
N 613 385 317 180 355 221
R
2 0.52 0.34 0.33 0.30 0.66 0.65
Error SD (cm) 1.3 1.1 1.0 1.0 4.5 3.8
Parameter estimate (PE) PE Rank PE Rank PE Rank PE Rank PE Rank PE Rank
Intercept (constant) 9.4 4.7 6.2 6.0 Intercept 72.6 57.0
Age at start
(years)
-0.31 2 -0.11 2 -0.18 2 -0.05 4 Age puberty onset (years) -4.0 1 -3.7 1
Weight at start
(SDS)
0.30 3 - - 0.19 3 0.40 1 Age - Bone age (years) 1.4 2 1.7 2
GH dose at year start
(mg/kg/day)
56.51 1 13.46 3 1.21
# 5 0.87
& 3 Mean GH dose
(mg/kg/week)
8.8 4 9.5 4
MPH (SDS) 0.11 * 4 - - 0.12
$ 4 - - Height - MPH
$
(SDS)
-1.3 3 -1.2 3
HV in previous year (cm/year) - - 0.30 1 0.26 1 0.21 2 _ _ _ _ _
* = based on Tanner references;
$ [8] = based on Prader references [9];
# = mg/kg/week;
&= ln IU/kg/week;
@ = based on GHD model (Ranke et al., 1999) [17].
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Figure 1 Studentized Residuals (y-axis) in relationship to the predicted growth (x-axis).a )1
st prepubertal year; b) 2
nd prepubertal year;
c) 3
rd prepubertal year, d) 4
th prepubertal year, and e) TPG (closed circles = males; open circles = females); a-d: X-axis in cm/year; e X-axis in cm.
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dation group was: R = 0.53 (p = 0.001) and the mean of
Studentized Residual was 0.0 (SD = 1.0) [Figure 2a, b].
Discussion
Most short stature children born SGA catch up within
the first two years of life; however, about 10-15% remain
permanently short [3]. Obviously, since the causes of
intrauterine as well as permanent growth impairment
are often unknown, the terminology used to define
these children is descriptive rather than causal [1]. GH
treatment in short children born SGA has been investi-
gated over many years. Both the US Food and Drug
Administration (FDA) and the European Agency for the
Evaluation of Medical Products (EMEA) have approved
GH for the treatment of short stature in children born
SGA and Silver-Russell syndrome, provided that other
causes of short stature are excluded, such as growth-
inhibiting medication, chronic diseases, endocrine disor-
ders, emotional deprivation, or syndromes associated
with short stature. GH treatment for short stature in
SGA children is standard practice today [18,19]. So far
only a few studies on SGA have documented the growth
response to GH until adult height [20-28]. The data sug-
gest that a considerable fraction of the short stature
children born SGA treated with GH does not reach a
normal height. Thus, an optimising of the treatment
approach with GH is mandatory.
T h er e s p o n s et oG Hc a nb ee x p r e s s e di nd i f f e r e n t
modes. Traditionally the response has been expressed in
terms of annual height velocity (cm/year) which can be
compared to normal age-related references either
directly or transformed into SD scores. During puberty
total height gain (cm) from the onset of puberty to the
end of growth can be described. In addition height velo-
city can be compared with empirical somatograms
derived from patients during GH therapy versus age and
sex. Such height velocity targets [29] have been pub-
lished for the first two prepubertal years for SGA chil-
dren [30]. Moreover, the response can be predicted
based on mathematical algorithms derived from the ana-
lyses of large cohorts of children with the same diagno-
sis treated with GH [31]. The observed and the
predicted growth can be compared and expressed as a
Studentized Residual; - an” index of responsiveness”.
We and others [32-34,17] ) have developed algorithms
(models) for the prediction of the response to GH and
have shown that the most important determinants of
first pre-pubertal year growth on GH in short children
born SGA including Silver Russell Syndrome (SRS) are
the dose of GH (the higher, the greater) and the age of
the children (the younger, the greater). We were also
B A
Figure 2 Validation group (N = 34) for the 3
rd prepubertal year model: a) Studentized Residuals (y-axis) in relationship to the
predicted growth (x-axis); b) correlation between predicted (x-axis) and observed (y-axis) height velocity (cm/year).
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Page 6 of 8able to show that the height velocity observed during
the first year is the major determinant of the second
pre-pubertal year growth response to GH in SGA [4].
U n l i k ei nG H Dt h e r ea r en oS G Ag r o w t hp r e d i c t i o n
models existing for the subsequent pre-pubertal treat-
ment years. The present analysis confirms that the SGA
prediction models developed for the first two prepuber-
tal years are suited to accurately predict height velocity
in other patients documented within KIGS, who by the
nature of the database are very heterogeneous. During
the third prepubertal year of GH treatment again the
observed previous height velocity and age are the most
important predictors of height velocity. During the
fourth year of GH treatment in SGA growth is only
marginally above the spontaneous normal growth rate.
Thus, most of the catch-up growth occurs during the
first three years on GH. Since the number of children
during the fourth prepubertal treatment year within
KIGS did not exceed two hundred it was not appropri-
ate to calculate an independent prediction model for
SGA. However, the fact that the fourth-year prediction
model for children with GHD [14] could be applied to
the SGA cohort indicates, that after most of catch-up
growth has occurred, similar mechanisms appear to be
involved in the response to GH of both disorders at that
stage of treatment.
Likewise, the number of individuals with all documen-
ted information required for the development of a dis-
ease-specific mathematical algorithm to predict TPG
was presently still too small within KIGS. However, the
models developed for male and female adolescents with
GHD [17] could be applied to adolescents with SGA
and gave accurate results. The models for TPG show
that the anthropometrical characteristics at puberty
onset are more important for TPG than the dose of GH,
which is of course the only factor which can be modi-
fied by the treating physician.
Conclusions
The presently available growth prediction models derived
from KIGS data are suited to predict height development
during the most relevant phases of growth in short chil-
dren born SGA. This will serve to adapt treatment mod-
alities in such a way that an optimal height outcome can
be achieved. The prediction models can be used to pro-
vide patients with a realistic expectation of treatment,
and may help to identify compliance problems or other
underlying causes of treatment failure.
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